CClinicalTrials.gg
Sign In
Not yet recruitingNCT06869109CXCL10Updated Mar 11, 2025

Serum CXCL10 and CRP Levels in Patients with Acne Vulgaris in Correlation with Disease Severity

An observational study in Acne Vulgaris, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 12 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2026, 6 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
88
Ages
12 Years to 40 Years
Sex
All
01

Study summary

the correlations between CXCL10 levels, CRP, and acne severity scores (e.g., Global Acne Grading System) suggest that CXCL10 could serve as a biomarker of inflammation and acne severity. Understanding the relationship between CXCL10, CRP, and acne severity may offer insights into novel therapeutic strategies targeting inflammatory pathways in acne.

Read the detailed description

Cross-sectional Observational Study. using 4 groups a 3 of different acne severity and controle one . the serum cxcl10 and crp will measured in each patient to correlate with disease severity

02

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • acne vulgaris
  • cxcl10
  • crp
03

In context

Acne Vulgaris

730 studies on the registry are indexed under Acne Vulgaris; 86 are open to participants now.

This study's planned enrollment of 88 is close to the median of 90 across 81 observational studies indexed under Acne Vulgaris.

Browse Acne Vulgaris studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

the patients with acne with different severity

Inclusion criteria

  1. Patients aged 12-40 years diagnosed with acne vulgaris.
  2. Both genders included.
  3. Patients with mild, moderate, or severe acne severity as determined by a validated scoring system (e.g., Global Acne Grading System).
  4. Patients not on systemic acne treatment (e.g., isotretinoin or antibiotics) or anti-inflammatory drugs.

Exclusion criteria

Exclusion Criteria:

  1. Patients with autoimmune diseases, systemic illnesses, acute infection or any other chronic inflammatory conditions that may affect CRP or CXCL10 levels.
  2. Pregnant or lactating individuals.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
88 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • mild acne group

    mild disease severity

    Diagnostic Test: serum cxcl10 · Diagnostic Test: serum crp

  • moderate acne group

    moderate disease severity

    Diagnostic Test: serum cxcl10 · Diagnostic Test: serum crp

  • severe acne group

    severe disease severity

    Diagnostic Test: serum cxcl10 · Diagnostic Test: serum crp

  • control group

    healthy people

    Diagnostic Test: serum cxcl10 · Diagnostic Test: serum crp

Interventions

  • Diagnostic testserum cxcl10

    serum blood sample to measure the cxcl10

  • Diagnostic testserum crp

    blood sample to measure crp

06

What researchers measure

Primary outcomes

  1. Correlation of CXCL10 and CRP levels with acne severity (GAG score).

    compare the result of serum cxcl10 and crp with disease severity

    Time frame: within one year after the result

Secondary outcomes

  1. Identify thresholds of CXCL10 and CRP for predicting moderate/severe acne

    the least result to identify the group

    Time frame: within one year after the result

  2. Explore potential differences based on sex or age groups

    the effect of age and sex on the result

    Time frame: within one year of the result

07

Study locations

1 site
  • Assiut University
    Assiut, 71515, Egypt
08

References and documents

Publications

  • Abdelrazik YT, Ali FM, Salek MS, Finlay AY. Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI). Br J Dermatol. 2021 Oct;185(4):711-724. doi: 10.1111/bjd.20391. Epub 2021 Jul 22. PubMed 33864247 ↗
  • Alsulaimani H, Kokandi A, Khawandanh S, Hamad R. Severity of Acne Vulgaris: Comparison of Two Assessment Methods. Clin Cosmet Investig Dermatol. 2020 Sep 28;13:711-716. doi: 10.2147/CCID.S266320. eCollection 2020. PubMed 33061511 ↗
  • Stańkowska A, Bergler-Czop B, Brzezińska-Wcisło L. Interleukins-6, -8 and -12p40 and C-reactive protein levels in patients with acne vulgaris with various severityof skin changes. Dermatology Review/Przegląd Dermatologiczny. 2020;107(4):308-22
  • Yang CC, Huang YT, Yu CH, Wu MC, Hsu CC, Chen W. Inflammatory facial acne during uncomplicated pregnancy and post-partum in adult women: a preliminary hospital-based prospective observational study of 35 cases from Taiwan. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1787-1789. doi: 10.1111/jdv.13667. Epub 2016 Apr 22. PubMed 27102946 ↗
  • Kutlu O, Karadag AS, Unal E, Kelekci KH, Yalcinkaya Iyidal A, Topaloglu Demir F, Aksoy B, Colgecen E, Tosun M, Emre S, Tatliparmak A, Demirseren DD, Kaya Ozden H, Ozturk M, Ozlu E, Chen W. Acne in pregnancy: A prospective multicenter, cross-sectional study of 295 patients in Turkey. Int J Dermatol. 2020 Sep;59(9):1098-1105. doi: 10.1111/ijd.14999. Epub 2020 Jun 20. PubMed 32562263 ↗
  • Ansar W, Ghosh S, Ansar W, Ghosh S. Inflammation and inflammatory diseases, markers, and mediators: role of CRP in some inflammatory diseases. Biology of C reactive protein in health and disease. 2016:67-107
  • Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990 Nov;12(5):1179-86. doi: 10.1002/hep.1840120517. PubMed 1699862 ↗
  • Yu H, Zhang B, Zhan Y, Yi Y, Jiang Q, Zhang Q, Wu Y, Wu M. Neutrophil extracellular trap-related mechanisms in acne vulgaris inspire a novel treatment strategy with adipose-derived stem cells. Sci Rep. 2024 Jan 17;14(1):1521. doi: 10.1038/s41598-024-51931-w. PubMed 38233540 ↗
  • Bowe WP, Logan AC. Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles. Lipids Health Dis. 2010 Dec 9;9:141. doi: 10.1186/1476-511X-9-141. PubMed 21143923 ↗
  • Jin Z, Song Y, He L. A review of skin immune processes in acne. Front Immunol. 2023 Dec 15;14:1324930. doi: 10.3389/fimmu.2023.1324930. eCollection 2023. PubMed 38193084 ↗
  • Liang J, Chen Y, Wang Z, Wang Y, Mu S, Zhang D, Wang Z, Zeng W. Exploring the association between rosacea and acne by integrated bioinformatics analysis. Sci Rep. 2024 Feb 6;14(1):3065. doi: 10.1038/s41598-024-53453-x. PubMed 38321132 ↗
  • Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012 Jan 28;379(9813):361-72. doi: 10.1016/S0140-6736(11)60321-8. Epub 2011 Aug 29. PubMed 21880356 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06869109
Lead sponsor
Assiut University
Responsible party
Dina Essam (physician assiut university student hospital, Assiut University) — Principal investigator
First posted
Mar 11, 2025
Start date
Mar 10, 2025 (estimated)
Primary completion
Mar 10, 2026 (estimated)
Completion
Apr 10, 2026 (estimated)
Last update
Mar 11, 2025

Study contacts

Dina Essam, physician
Contact
dina.14224214@med.aun.edu.eg
+201027664829
Doaa Samir, prof
study director · Assiut University
Ahmed Shawky, prof
study director · Assiut University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acne Vulgaris→

Other studies from this sponsor

Assiut University

Start the discussion